US 11,856,970 B2
Bacillus subtilis for animal feed
Dorthe Sandvang, Hoersholm (DK); Ole Knudsmark Sjoeholm, Hoersholm (DK); Line Skjoet-Rasmussen, Hoersholm (DK); and Jette Mundus Nielsen, Hoersholm (DK)
Assigned to Chr. Hansen A/S, Hoersholm (DK)
Appl. No. 16/471,298
Filed by CHR. HANSEN A/S, Hoersholm (DK)
PCT Filed Jan. 18, 2019, PCT No. PCT/EP2019/051262
§ 371(c)(1), (2) Date Jun. 19, 2019,
PCT Pub. No. WO2019/141815, PCT Pub. Date Jul. 25, 2019.
Claims priority of application No. 18152596 (EP), filed on Jan. 19, 2018.
Prior Publication US 2021/0329944 A1, Oct. 28, 2021
Int. Cl. A23K 50/40 (2016.01); A01N 63/22 (2020.01); A23K 10/18 (2016.01); C12N 1/20 (2006.01); C12R 1/125 (2006.01)
CPC A23K 50/40 (2016.05) [A01N 63/22 (2020.01); A23K 10/18 (2016.05); C12N 1/205 (2021.05); C12R 2001/125 (2021.05)] 12 Claims
 
1. A method for inhibiting a bacterial colonization or bacterial infection by one or more of Staphylococcus pseudintermedius, Staphylococcus carnosus, Salmonella enterica, Salmonella Newport, Streptococcus canis, Escherichia coli, and Clostridium perfringens, the method comprising administering to an animal in need thereof an effective amount of a Bacillus subtilis strain deposited at Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany (DSMZ) under accession number DSM 32685, wherein strain DSM 32685:
(i) exhibits susceptibility to ampicillin, vancomycin, gentamicin, kanamycin, streptomycin, erythromycin, clindamycin, tetracycline, and chloramphenicol when tested under CLSI guidelines M07-A8 and M45-A2;
(ii) exhibits an inhibition zone of at least 1 mm for Staphylococcus pseudintermedius, Escherichia coli, and Salmonella enterica;
(iii) reduces the growth rate of Streptococcus canis by at least one log10 growth in 24 hours; and
(iv) inhibits growth of Staphylococcus carnosus, Salmonella Newport, and Clostridium perfringens.